Bristol Myers says admilparant preserves lung function
Bristol Myers says 60 mg of admilparant preserved lung function in a 1,255-person trial, while the 120 mg dose missed statistical significance.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Reuters reported that Bristol Myers Squibb said its experimental treatment admilparant achieved the primary objective in a late-stage trial involving people with idiopathic pulmonary fibrosis, a severe condition marked by scarring of the lungs.
The study enrolled 1,255 participants and compared twice-daily doses of 60 mg and 120 mg with placebo. After 52 weeks, the lower dose delivered a statistically significant benefit in preserving lung function. Researchers measured that function through forced vital capacity, the amount of air a person can forcefully exhale after a deep breath. The 120 mg dose did not produce a statistically significant improvement over the same period. Bristol Myers said tolerability was generally favorable at both doses, while treatment stoppages linked to side effects remained low and similar to placebo.
why it matters
The company’s shares gained more than 6% in premarket trading, indicating a strong market response to the trial outcome and the differing results for the two doses.
instruments
sources
- Bristol Myers' lung disease drug meets main goal in late-stage trial — Reuters, 12 October 2026 at 10:54 UTC
- Bristol Myers cancer therapy meets main goal in late-stage study — Reuters, 12 October 2026 at 11:09 UTC
- Bristol Myers' drug improves lung function in late-stage trial — Reuters, 12 October 2026 at 11:12 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗